PloS one, 2013-01, Vol.8 (1), p.e54634-e54634
2013
Details
- Autor(en) / Beteiligte
- Titel
- Treatment with n-3 polyunsaturated fatty acids overcomes the inverse association of vitamin D deficiency with inflammation in severely obese patients: a randomized controlled trial
- Ist Teil von
- PloS one, 2013-01, Vol.8 (1), p.e54634-e54634
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2013
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Obesity affects the vitamin D status in humans. Vitamin D and long-chain n-3 polyunsaturated fatty acids (PUFA) provide benefit for the prevention of fractures and cardiovascular events, respectively, and both are involved in controlling inflammatory and immune responses. However, published epidemiological data suggest a potential interference of n-3 PUFA supplementation with vitamin D status. Therefore, we aimed to investigate in a randomized controlled clinical trial whether treatment with long chain n-3 PUFA affects vitamin D status in severely obese patients and potential interrelations of vitamin D and PUFA treatment with inflammatory parameters. Fifty-four severely obese (BMI ≥ 40 kg/m2) non-diabetic patients were treated for eight weeks with either 3.36 g/d EPA and DHA or the same amount of butter fat as control. Changes in serum 25-hydroxy-vitamin D [25(OH)D] concentrations, plasma fatty acid profiles and circulating inflammatory marker concentrations from baseline to end of treatment were assessed. At baseline 43/54 patients were vitamin D deficient (serum 25(OH)D concentration <50 nmol/l). Treatment with n-3 PUFA did not affect vitamin D status (P = 0.91). Serum 25(OH)D concentration correlated negatively with both IL-6 (P = 0.02) and hsCRP serum concentration (P = 0.03) at baseline. Strikingly, the negative correlations of 25(OH)D with IL-6 and hsCRP were lost after n-3 PUFA treatment. In conclusion, vitamin D status of severely obese patients remained unaffected by n-3 PUFA treatment. However, abrogation of the inverse association of 25(OH)D concentration with inflammatory markers indicated that n-3 PUFA treatment could compensate for some detrimental consequences of vitamin D deficiency. ClinicalTrials.gov NCT00760760.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6203eISSN: 1932-6203DOI: 10.1371/journal.pone.0054634Titel-ID: cdi_plos_journals_1327868333
- Format
- –
- Schlagworte
- Adult, Alfacalcidol, Biology, Body mass, Calcifediol, Cancer, Care and treatment, Chains, Chromatography, Clinical trials, Diabetes, Diabetes mellitus, Diabetics, Drug dosages, Eicosapentaenoic Acid - blood, Endocrinology, Enzymes, Epidemiology, Fatty acids, Fatty Acids, Omega-3 - therapeutic use, Female, Fractures, Gene expression, Heart attacks, Humans, Hypertension, Immune response, Immunoassay, Immunotherapy, Inflammation, Inflammation - blood, Inflammation - complications, Inflammation - drug therapy, Insulin resistance, Interleukin 6, Interleukin-6 - blood, Internal medicine, Laboratories, Male, Medical research, Medicine, Medicine, Experimental, Metabolism, Middle Aged, Nutrient deficiency, Obesity, Obesity - blood, Obesity - complications, Older people, Patients, Plasma, Polyunsaturated fatty acids, Product development, Randomization, Statistical analysis, Supplementation, Supplements, Treatment Outcome, Type 2 diabetes, Unsaturated fatty acids, Vitamin D, Vitamin D - analogs & derivatives, Vitamin D - blood, Vitamin D deficiency, Vitamin D Deficiency - blood, Vitamin D Deficiency - complications, Vitamin D Deficiency - drug therapy, Vitamin deficiency